

CAPACITY-COVID: European registry to determine the role of cardiovascular disease in the COVID-19 pandemic

Authors: Marijke Linschoten MD and Folkert W. Asselbergs MD, PhD FESC on behalf of CAPACITY-COVID collaborative consortium

From the emerging literature, cardiovascular disease appears to play a prominent role in the COVID-19 pandemic on multiple levels: (1) patients with cardiovascular risk factors and pre-existent cardiovascular disease seem to have an increased risk of a poor outcome^{1,2,3} (2) patients with COVID-19 have, also in the absence of underlying cardiovascular disease been reported to develop cardiovascular complications^{3,4,5} (3) therapeutics currently prescribed in an experimental setting such as antimalarial- and antiviral drugs have known cardiovascular side effects and (4) there are concerns, especially on social media, regarding the safety of angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) in relation to COVID-19^{3,6}. Insufficient evidence is currently available to guide clinicians in the management of these patients.

To accelerate knowledge on the role of cardiovascular disease in the COVID-19 pandemic, standardized and coordinated data collection on a large scale is of pivotal importance. For this reason, we launched the CAPACITY-COVID (www.capacity-covid.eu) registry last week (Figure 1). CAPACITY-COVID offers a comprehensive data collection tool that facilitates uniform data collection of patients infected with SARS-CoV-2. The registry builds upon the Case Report Form (CRF)(<https://isaric.tghn.org/covid-19-clinical-research-resources/>) released by the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) and World Health Organisation (WHO) in response to the COVID-19 outbreak. By collecting information in the registry in a standardized manner, we hope this initiative can aid in providing more insight into (1) the incidence and pattern of cardiovascular complications in patients with COVID-19 and (2) the vulnerability and clinical course of COVID-19 in patients with an underlying cardiovascular disease.

Within CAPACITY-COVID, the ISARIC-WHO CRF has been extended with multiple additional data collection instruments on cardiovascular risk factors, the use of cardiovascular medication and NSAIDs, cardiac biomarkers, ECG, echocardiography, cardiac MRI, chest CT, invasive cardiac procedures and cardiac complications. Furthermore, cardiac outcome during admission at 7- and 30-days are collected. A specification on all variables included can be found in the REDCap Codebook on our website.

All patients with a highly suspected or proven infection with SARS-CoV-2 are eligible for inclusion in CAPACITY-COVID. We strongly encourage multidisciplinary collaborative efforts to collect the data, to increase the coverage of inclusion across various departments involved in the care of these patients. On the short term, the primary focus of the consortium will be to develop prognostic models with the collected data. Since the launch of the registry, 50 centres across 3 countries have joined. We hereby would like to invite other centres to participate in CAPACITY-COVID. To allow a quick set up of the project for centres that want to participate, we have

developed a portfolio of resources, including the study protocol, patient information form and standard operating procedures that are all freely available. Please see the infographic (Figure 2) on the steps you have to take to join the consortium. For more information visit our website: www.capacity-covid.eu

Figure legends:

Figure 1: Infographic

Figure 2: Logo of the CAPACITY-COVID registry

Acknowledgements:

Dutch CardiovascularAlliance (DCVA)

Dutch Association for Cardiology (NVVC)

Dutch Network for Cardiovascular Research (WCN)

Netherlands Heart Registration (NHR)

Netherlands Heart Institute (NHI)

Dutch Heart Foundation (DHF)

Dutch Patient Organisation for Patients with Cardiovascular Diseases (Harteraad)

Disclosures:

None to declare.

References:

1. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA*. 2020. doi: 10.1001/jama.2020.2648.
2. Yang J, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. *Int J Infect Dis*. 2020. pii: S1201-9712(20)30136-3. doi: 10.1016/j.ijid.2020.03.017.
3. Zheng YY, et al. COVID-19 and the cardiovascular system. *Nat Rev Cardiol*. 2020. doi: 10.1038/s41569-020-0360-5.
4. Huang C, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020; 395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5.
5. Inciardi RM, et al. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol*. 2020. doi: 10.1001/jamacardio.2020.1096.

6. de Simone, G. Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers. *European Society of Cardiology*. 2020.